A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC–CTG) IND 130

Investigational New Drugs ◽

10.1007/s10637-005-2904-2 ◽

2005 ◽

Vol 23 (5) ◽

pp. 445-453 ◽

Author(s):

Karen A. Gelmon ◽

Karl Belanger ◽

Denis Soulieres ◽

Carolyn Britten ◽

Stephen Chia ◽

...

Keyword(s):

Clinical Trials ◽

Phase I ◽

National Cancer Institute ◽

Download Full-text

A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131

Annals of Oncology ◽

10.1093/annonc/mdh278 ◽

2004 ◽

Vol 15 (7) ◽

pp. 1115-1122 ◽

Author(s):

K.A. Gelmon ◽

D. Stewart ◽

K.N. Chi ◽

S. Chia ◽

C. Cripps ◽

...

Keyword(s):

Clinical Trials ◽

Phase I ◽

National Cancer Institute ◽

Phase I Study ◽

Download Full-text

A phase I study of T900607 given once every three weeks in patients with advanced refractory cancer. A National Cancer Institute of Canada-Clinical Trials Group Study (NCIC CTG-IND 130)

European Journal of Cancer ◽

10.1016/s0959-8049(01)80593-1 ◽

2001 ◽

Vol 37 ◽

pp. S30

Author(s):

K.A. Gelmon ◽

K. Belanger ◽

C. Britton ◽

D. Soulières ◽

S. Janke ◽

...

Keyword(s):

Clinical Trials ◽

Phase I ◽

National Cancer Institute ◽

Download Full-text

Phase I study of triple drug combination of CPT-11 (C), Oxaliplatin (O) and Tomudex (T) (COT) in previously untreated metastatic colorectal cancer (MCRC): National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), IND.135

European Journal of Cancer ◽

10.1016/s0959-8049(01)81580-x ◽

2001 ◽

Vol 37 ◽

pp. S295

Author(s):

J.A. Maroun ◽

D. Jonker ◽

L. Seymour ◽

R. Goel ◽

W. Kocha ◽

...

Keyword(s):

Colorectal Cancer ◽

Clinical Trials ◽

Phase I ◽

Metastatic Colorectal Cancer ◽

National Cancer Institute ◽

Drug Combination ◽

Download Full-text

Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115

Annals of Oncology ◽

10.1093/annonc/mdl165 ◽

2006 ◽

Vol 17 (9) ◽

pp. 1371-1378 ◽

Author(s):

J.A. Maroun ◽

K. Belanger ◽

L. Seymour ◽

S. Matthews ◽

J. Roach ◽

...

Keyword(s):

Clinical Trials ◽

Phase I ◽

Solid Tumors ◽

National Cancer Institute ◽

Standard Therapy ◽

Download Full-text

93 POSTER Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors (VEGFR), in combination with oxaliplatin and Infusional 5-Fu (mFOLFOX6) in patients with advanced colorectal cancer (CRC): a study of the National Cancer Institute of Canada Clinical Trials Group

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(06)70099-4 ◽

2006 ◽

Vol 4 (12) ◽

pp. 32 ◽

Author(s):

E. Chen ◽

D. Jonker ◽

M. Maclean ◽

J. Wells ◽

S. Mathews ◽

...

Keyword(s):

Colorectal Cancer ◽

Vascular Endothelial Growth Factor ◽

Clinical Trials ◽

Growth Factor ◽

Phase I ◽

National Cancer Institute ◽

Phase I Study ◽

Advanced Colorectal Cancer ◽

Vascular Endothelial ◽

Endothelial Growth Factor

Download Full-text

Phase I study of paclitaxel (TaxolR) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group

Lung Cancer ◽

10.1016/s0169-5002(97)89561-x ◽

1996 ◽

Vol 16 (1) ◽

pp. 122

Keyword(s):

Lung Cancer ◽

Clinical Trials ◽

Phase I ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

National Cancer Institute ◽

Phase I Study ◽

Small Cell Lung

Download Full-text

A phase I study of BAY 38-3441 given as a short infusion daily for five days every 3 weeks. a National Cancer Institute of Canada Clinical Trials Group Study

European Journal of Cancer ◽

10.1016/s0959-8049(01)80750-4 ◽

2001 ◽

Vol 37 ◽

pp. S73

Author(s):

L. Seymour ◽

L. Siu ◽

G. Batist ◽

J. Cammisano ◽

M. Maclean ◽

...

Keyword(s):

Clinical Trials ◽

Phase I ◽

National Cancer Institute ◽

Phase I Study ◽

Download Full-text

A phase I study of ZD0473 and docetaxel given once every three weeks in patients with advanced refractory cancer. A National Cancer Institute of Canada-Clinical Trials Group Study (NCIC CTG-IND 131)

European Journal of Cancer ◽

10.1016/s0959-8049(01)80746-2 ◽

2001 ◽

Vol 37 ◽

pp. S72 ◽

Author(s):

K.A. Gelmon ◽

D. Stewart ◽

D. Ayers ◽

D. Fry ◽

L. Douglas ◽

...

Keyword(s):

Clinical Trials ◽

Phase I ◽

National Cancer Institute ◽

Download Full-text

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

Investigational New Drugs ◽

10.1007/s10637-005-5860-y ◽

2005 ◽

Vol 23 (2) ◽

pp. 147-155 ◽

Author(s):

G. Goss ◽

H. Hirte ◽

W. H. Miller ◽

I. A. J. Lorimer ◽

D. Stewart ◽

...

Keyword(s):

Clinical Trials ◽

Phase I ◽

Solid Tumors ◽

National Cancer Institute ◽

Phase I Study ◽

Download Full-text

The National Cancer Institute Phase I Study of 2′,3′-Dideoxyinosine Administration in Adults with AIDS or AIDS-Related Complex: Analysis of Activity and Toxicity Profiles

Clinical Infectious Diseases ◽

10.1093/clinids/12.supplement_5.s522 ◽

1990 ◽

Vol 12 (Supplement_5) ◽

pp. S522-S533 ◽

Author(s):

Robert Yarchoan ◽

Hiroaki Mitsuya ◽

James M. Pluda ◽

Katby S. Marczyk ◽

Rose V. Thomas ◽

...

Keyword(s):

Phase I ◽

National Cancer Institute ◽

Phase I Study ◽

Complex Analysis ◽

Aids Related Complex ◽

Related Complex

Download Full-text